Denali Therapeutics Inc (NASDAQ: DNLI) kicked off on Tuesday, down -3.78% from the previous trading day, before settling in for the closing price of $17.47. Over the past 52 weeks, DNLI has traded in a range of $10.57-$24.34.
Healthcare Sector giant saw their annual sales slid by -4.46% over the last five years. While this was happening, its average annual earnings per share was recorded -16.43%. With a float of $138.96 million, this company’s outstanding shares have now reached $146.63 million.
The firm has a total of 422 workers. Let’s measure their productivity.
Denali Therapeutics Inc (DNLI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 11.01%, while institutional ownership is 89.27%. The most recent insider transaction that took place on Dec 04 ’25, was worth 35,758. Before that another transaction happened on Aug 12 ’25, when Company’s COFO and Secretary sold 2,937 for $13.58, making the entire transaction worth $39,884. This insider now owns 242,346 shares in total.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.67 earnings per share (EPS), higher than consensus estimate (set at -0.85) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.04% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Take a look at Denali Therapeutics Inc’s (DNLI) current performance indicators. Last quarter, stock had a quick ratio of 9.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -2.84 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Analysing the last 5-days average volume posted by the [Denali Therapeutics Inc, DNLI], we can find that recorded value of 1.36 million was lower than the volume posted last year of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 14.24%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 52.68%, which indicates a significant increase from 3.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.96 in the past 14 days, which was higher than the 0.86 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.18, while its 200-day Moving Average is $15.05. Now, the first resistance to watch is $17.38. This is followed by the second major resistance level at $17.94. The third major resistance level sits at $18.27. If the price goes on to break the first support level at $16.48, it is likely to go to the next support level at $16.15. Should the price break the second support level, the third support level stands at $15.59.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
The company with the Market Capitalisation of 2.63 billion has total of 146,662K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -422,770 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -126,900 K.
